Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Luden's Echinacea Throat Drops Are Not Dietary Supplements, FDA Says

This article was originally published in The Tan Sheet

Executive Summary

FDA continues to hold the position that throat or cough drops cannot be classified as dietary supplements, according to a Nov. 4 "courtesy" letter to Hershey Foods recently made available by the agency. Luden's Throat Drops/Herbal Echinacea Supplement with echinacea, rose hips and vitamin C "does not appear to meet the statutory definition of a dietary supplement...and therefore, can not be marketed as a dietary supplement," FDA says (1see box, p. 8). Hershey launched the extension to the Luden's line in August (2see story, p. 6).

You may also be interested in...



Supplement/OTC Combos Have Precedents In Other Categories, Firms State

Prior sale of combination products such as drug/ devices or drug/biologics set a precedent for selling dietary supplement/OTC combination products, B.F. Ascher and Omni Nutraceuticals maintain in separate letters sent to FDA Nov. 6

Supplement/OTC Combos Have Precedents In Other Categories, Firms State

Prior sale of combination products such as drug/ devices or drug/biologics set a precedent for selling dietary supplement/OTC combination products, B.F. Ascher and Omni Nutraceuticals maintain in separate letters sent to FDA Nov. 6

Supplement/OTC Combos Have Precedents In Other Categories, Firms State

Prior sale of combination products such as drug/ devices or drug/biologics set a precedent for selling dietary supplement/OTC combination products, B.F. Ascher and Omni Nutraceuticals maintain in separate letters sent to FDA Nov. 6

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel